Fusion Pharmaceuticals Inc.
FUSN · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 41.5% | 1.5% | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 35% | -3,931.1% | -3,813.7% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -4,235.9% | -5,972.8% | -5,651.5% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -4,588.8% | -5,996.7% | -5,628.3% | – |
| EPS Diluted | -1.45 | -2 | -1.9 | -3.56 |
| % Growth | 27.5% | -5.3% | 46.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |